Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a ...

A new gene-targeting strategy that boosts a crucial brain protein could pave the way for the first effective treatment for ...

Researchers show two distinct MECP2 mutations in Rett syndrome elevate miRNA-126-3p, lowering ZO-1 and weakening blood-brain ...

A team of researchers at Baylor College of Medicine and the Duncan Neurological Research Institute (Duncan NRI) at Texas ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

Researchers have discovered a new way to increase a key brain protein damaged in Rett syndrome, a rare genetic disorder that affects thousands of children worldwide. Early studies in mice and ...

According to the Mayo Clinic, Rett syndrome is a developmental disorder that affects the way the brain develops Courtesy of Shelly Balboa When Joseph and Shelly Balboa's daughter was 2 months old, the ...

A European regulatory body adopted a negative opinion regarding Acadia Pharmaceuticals' application for trofinetide, its treatment for Rett syndrome, a rare neurodevelopmental disorder seen in ...

A team of researchers at Texas Children's Duncan Neurological Research Institute (NRI) and Baylor College of Medicine report ...

Improvements in motor function and memory suggest human neurodevelopmental disorders may be amenable to treatment, even after onset of symptoms. According to a researcher, neurodevelopmental disorders ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

Rett syndrome is a neurodevelopmental disorder that primarily affects girls, most of whom have mutations in the transcription regulatory gene MECP2. However, mutations in MECP2 also have been ...